Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy

Hemoglobin

Volumn 34, Issue 3, 2010, Pages 204-209

  Kolnagou, Annita ^a   Kontoghiorghes, George J ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

Chelation therapy; Deferasirox (DFRA); Deferiprone (L1); Deferoxamine (DFO); Iron overload; Normal iron stores; Thalassemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; DEFERIPRONE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; IRON; UREA;

ADULT; AGRANULOCYTOSIS; BIOCHEMISTRY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONFERENCE PAPER; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; HEMOLYSIS; HUMAN; IRON STORAGE; KIDNEY FUNCTION; LIVER FUNCTION; MALE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; SPLENECTOMY; THALASSEMIA MAJOR;

ADULT; BETA-THALASSEMIA; CHELATION THERAPY; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; MALE; MIDDLE AGED; PYRIDONES; TIME FACTORS;

EID: 77953249366     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2010.485890     Document Type: Conference Paper

References (10)

1. Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxaminefor the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The protocol of the International Committee on Oral Chelators. Hemoglobin. 2006; 30(2):239-249.
2. Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes GJ. Long term comparative studies in thalassemia patients treated with deferoxamine or deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin. 2008;32(1-2):41-47.
3. Kolnagou A, Michaelides Y, Kontos C, Kyriacou K, Kontoghiorghes GJ. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin 2008;32(1-2):17-28.
4. Kontoghiorghes GJ.A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of ironoverload in thalassemia and other chronically transfused patients. Hemoglobin. 2009;33(5):332-338.
5. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148(3):466-475.
6. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876-1884.
7. Kontoghiorghes GJ. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci. (Elite Ed.) 2009;1:161-178.
8. Kontoghiorghes GJ, Kolnagou A, Peng CT, Shah SV, Aessopos A. Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opin Drug Saf. 2010;9(2): 201-206.
9. Aessopos A, Kati M, Farmaki D, et al. Intensive chelation therapy in β-thalassemia and possible adverse cardiac effects of desferrioxamine. Int J Haematol. 2007;86(3):212-215.
10. Kolnagou A, Yazman D, Economides Ch, Eracleous E, Kontoghiorghes GJ. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol. Hemoglobin. 2009;33(5):312-322.